Crystal Pharmatech Officially Launches Global Headquarters R&D Building and Files IPO Prospectus
On January 2, 2025, Suzhou CRYSTAL Pharmatech Co., Ltd. (hereinafter referred to as “CRYSTAL Pharmatech”) officially announced that its facility located at No. 288 Jiangyun Road, Suzhou Industrial Park,CRYSTAL Pharmatech Global Headquarters R&D BuildingFully launched, CRYSTAL Pharmatech has officially entered a new phase of rapid development.
Since construction commenced in October 2021, the Crystal Pharmatech Headquarters Base has undergone three years of meticulous planning and craftsmanship. On August 15, 2024, Phase I of the headquarters base—the Crystal Building—successfully passed completion acceptance and was officially put into use recently. As the landmark building of the headquarters base, the Crystal Building integrates efficient and advanced office and R&D functions. It features over 10,927 square meters of R&D laboratory space and approximately 16,428 square meters of office area, aiming to create a comfortable and open work environment that fosters team collaboration and the exchange of creative ideas.
With its distinctive “C-shaped” design, the Crystal Building not only cleverly echoes the “Crystal” in CRYSTAL Pharmatech’s English name, but also symbolizes the company’s steadfast commitment to pursuing excellence and leading the industry. Its overall form resembles open arms, welcoming every partner and reflecting CRYSTAL Pharmatech’s philosophy of openness and inclusivity. CRYSTAL Pharmatech looks forward to collaborating with more innovative pharmaceutical companies to jointly advance the R&D of novel drugs, bringing more treatment options and hope to patients worldwide!
With the official inauguration of CRYSTAL Pharmatech’s headquarters base, CRYSTAL Pharmatech will continue to deepen its roots in Suzhou Industrial Park. Leveraging its global R&D and manufacturing footprint across Suzhou (China), the United States, and Canada, the company aims to attract top-tier talent in research and development, production, and management, thereby delivering professional, efficient, and sustainable R&D and manufacturing services to pharmaceutical companies worldwide.
Meanwhile, Crystal Tower has specially opened up selected R&D and office spaces (Crystal Campus), aiming to attract promising biopharmaceutical startups to move in with a turnkey solution, in alignment with CRYSTAL Pharmatech’s strategy of strategic investments across the upstream and downstream value chain. For high-quality tenants whose profiles align with CRYSTAL Pharmatech’s strategic focus, the company will provide comprehensive support, including strategic investment and ancillary services, to jointly drive the development of the biopharmaceutical industry.
As the headquarters base commences operations,Dr. Minhua Chen, Co-founder, Chairman and CEO of CRYSTAL PharmatechIt stated: “Standing at a new starting point, CRYSTAL Pharmatech will continue to deepen its core business areas of crystal form research, formulation development, and manufacturing services, while continuously improving and enhancing its R&D and production technology platforms to provide professional, high-quality, and efficient services to global customers.”
Since its establishment in 2010, CRYSTAL Pharmatech has provided drug polymorph and formulation R&D and manufacturing services to more than 1,000 innovative pharmaceutical companies worldwide. Adhering to the philosophy of “tailoring ‘right-first-time’ polymorphs and formulations,” CRYSTAL helps clients efficiently and accurately advance preclinical candidate compounds into clinical studies and commercialization, thereby driving the rapid development of innovative drugs through advanced polymorph and formulation technologies.
CRYSTAL Pharmatech also extends its sincere gratitude to the Suzhou Municipal Government, Suzhou Industrial Park, Suzhou Dushu Lake Higher Education and Innovation District, and Suzhou BioBAY for their longstanding support and assistance. It is precisely because of this strong backing that CRYSTAL Pharmatech has been able to achieve steady development.
New Location, New Horizon: Setting Sail on a New Journey. Leveraging the momentum of our headquarters’ relocation, CRYSTAL Pharmatech is embarking on a new chapter!
CRYSTAL Pharmatech is a technology-driven CRO/CDMO specializing in drug polymorph research, formulation development and manufacturing, and clinical supply. It is committed to providing tailored “right-first-time” polymorph and formulation solutions for small-molecule new drug clients, rapidly advancing your compounds from lead optimization or preclinical candidate stages to Phase I clinical trials and beyond, enhancing their competitiveness within the same target and disease areas, and maximizing their commercial value.
CRYSTAL Pharmatech, founded in 2010, operates R&D and manufacturing centers in Suzhou (China), New Jersey (USA), and Toronto (Canada), supported by a professional team of over 250 members. Leveraging innovative technologies and robust scientific capabilities, CRYSTAL Pharmatech has partnered with more than 1,000 pharmaceutical companies worldwide, providing specialized technical solutions for over 2,000 new drug compounds:
•Among the top 20 innovative pharmaceutical companies in China, 19 have chosen CRYSTAL Pharmatech’s services.
• Eight of the top 10 pharmaceutical companies globally are clients of CRYSTAL Pharmatech.
We look forward to partnering with you to accelerate new drug development, enabling patients to access high-quality medicines sooner.